In a filing, CorMedix Inc revealed its EVP, Chief Commercial Officer Mistry Erin acquired Company’s shares for reported $14985.0 on Oct 31 ’24. In the deal valued at $9.99 per share,1,500 shares were bought. As a result of this transaction, Mistry Erin now holds 52,011 shares worth roughly $0.73 million.
Then, Hurlburt Elizabeth sold 140,027 shares, generating $1,565,670 in total proceeds. Upon selling the shares at $11.18, the EVP now owns 45,397 shares.
Before that, Hurlburt Elizabeth bought 140,027 shares. CorMedix Inc shares valued at $1,556,416 were divested by the Officer at a price of $11.12 per share.
Leerink Partners initiated its CorMedix Inc [CRMD] rating to an Outperform in a research note published on March 07, 2025; the price target was $18. A number of analysts have revised their coverage, including D. Boral Capital’s analysts, who began to cover the stock in mid January with a ‘”a Buy”‘ rating. Rodman & Renshaw began covering CRMD with “Buy” recommendation on August 26, 2024. RBC Capital Mkts started covering the stock on August 10, 2023. It rated CRMD as “an Outperform”.
Price Performance Review of CRMD
On Friday, CorMedix Inc [NASDAQ:CRMD] saw its stock jump 0.89% to $14.10. Over the last five days, the stock has gained 11.06%. CorMedix Inc shares have risen nearly 74.14% since the year began. Nevertheless, the stocks have risen 166.13% over the past one year. While a 52-week high of $13.99 was reached on 06/09/25, a 52-week low of $3.61 was recorded on 04/07/25. SMA at 50 days reached $9.91, while 200 days put it at $9.64.
Levels Of Support And Resistance For CRMD Stock
The 24-hour chart illustrates a support level at 13.49, which if violated will result in even more drops to 13.00. On the upside, there is a resistance level at 14.23. A further resistance level may holdings at 14.48. The Relative Strength Index (RSI) on the 14-day chart is 75.22, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.00, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 10.63%. Stochastics %K at 92.97% indicates the stock is a selling.
The most recent change occurred on February 17, 2021 when Needham began covering the stock and recommended ‘”a Buy”‘ rating along with a $31 price target.
